Edgar A. MuellerMichele van VugtWilhelm KirchKim AndrianoPhilip HuntPatricia Ibarra de PalaciosDresden University Faculty of Medicine and University Hospital Carl Gustav CarusMahidol UniversityUniversity of AmsterdamNovartis Pharmaceuticals CorporationNovartis Horsham Research CentreNovartis International AG2018-08-202018-08-202006-11-01Acta Tropica. Vol.100, No.1-2 (2006), 41-530001706X2-s2.0-33751504559https://repository.li.mahidol.ac.th/handle/20.500.14594/23295To demonstrate the superiority of the six-dose over the four-dose regimen of artemether-lumefantrine (co-artemether, Coartem®) in patients >12 years, data from 11 randomized clinical trials were pooled and analyzed. A total of 1368 patients with uncomplicated Plasmodium falciparum malaria (six-dose: 598; four-dose: 770) were included in the analysis, together with 717 patients treated with comparators. Analysis of the 28-day cure rate based on the ITT and evaluable populations yielded corrected cure rates for the six-dose regimen of 87% and 97% compared with 74% and 87%, respectively, with the four-dose regimen (P < 0.0001, for both comparisons). For mefloquine/artesunate, the most frequently used comparator, cure rates were 87% and 99%, respectively. The six-dose regimen was well tolerated and not markedly different to the four-dose regimen. The main finding of our analysis is that the six-dose regimen of co-artemether is more effective than the four-dose regimen in adolescents and adults without compromising safety. © 2006 Elsevier B.V. All rights reserved.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS10.1016/j.actatropica.2006.09.007